The humanized monoclonal antibody, chimeric antigen receptor T (CAR-T) cells and the antibody drug conjugates (ADC) that specifically targeted LILRB4 could significantly inhibit the progression of AML [39–41], therefore, LILRB4 has been as a potential target for tumor therapy [38]. This evidence concerns the gene LILRB4 and acute myeloid leukemia.